Alopecia androgenetica maschile

Translated title of the contribution: Male pattern hair loss

A. Alinovi, L. Barbieri, S. Calvieri, P. De Giacomo, M. Guarrera, B. M. Piraccini, A. Rebora, A. Rossi, A. Tosti

Research output: Contribution to journalArticle

Abstract

Androgenetic alopecia is the most frequent cause of hair loss affecting at least 50% of men by the age of 50. Male pattern hair loss affect the front-vertical scalp. Hairs in this area progressively become like vellus hairs. The development of androgenetic alopecia requires the interaction of genetic and hormonal factors. Although there is agreement that it is an inherited condition, it may not be genetically homogeneous. Several data have confirmed the significant role of androgens in the development of androgenetic alopecia. Dihydrotestosterone is currently thought to be the most potent androgen affecting the human hair growth cycle, with adverse effects in male pattern hair loss. The enzyme 5α-reductase is responsible for catalyzing the conversion of testosterone to dihydrotestosterone. It is now known that two separate isoenzymes of 5α-reductase exist: type I and type II, specifically localized within the hair follicle itself and in the innermost layer of the outer root sheath. The importance of type II 5α-reductase in the development of androgenetic alopecia is demonstrated by the evidence that individuals with hereditary type II 5α-reductase deficiency do not develop androgenetic alopecia. In men, the diagnosis of androgenetic alopecia can usually be confirmed by medical history and physical examination alone. Androgenetic alopecia can be treated with oral finasteride (inhibitor of type II 5α-reductase) or topical minoxidil. Oral finasteride at the dosage of 1 mg/day produced clinical improvement in up to 66% of patients treated for 2 years. Moreover the exact role of the hair specialist is discussed and the dermatologist is confirmed as the more indicated specialist and for the field.

Original languageItalian
Pages (from-to)7-19
Number of pages13
JournalGiornale Italiano di Dermatologia e Venereologia
Volume136
Issue number1
Publication statusPublished - 2001

Fingerprint

Alopecia
Oxidoreductases
Hair
Finasteride
Dihydrotestosterone
Androgens
Minoxidil
Hair Follicle
Scalp
Isoenzymes
Physical Examination
Testosterone

ASJC Scopus subject areas

  • Dermatology

Cite this

Alinovi, A., Barbieri, L., Calvieri, S., De Giacomo, P., Guarrera, M., Piraccini, B. M., ... Tosti, A. (2001). Alopecia androgenetica maschile. Giornale Italiano di Dermatologia e Venereologia, 136(1), 7-19.

Alopecia androgenetica maschile. / Alinovi, A.; Barbieri, L.; Calvieri, S.; De Giacomo, P.; Guarrera, M.; Piraccini, B. M.; Rebora, A.; Rossi, A.; Tosti, A.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 136, No. 1, 2001, p. 7-19.

Research output: Contribution to journalArticle

Alinovi, A, Barbieri, L, Calvieri, S, De Giacomo, P, Guarrera, M, Piraccini, BM, Rebora, A, Rossi, A & Tosti, A 2001, 'Alopecia androgenetica maschile', Giornale Italiano di Dermatologia e Venereologia, vol. 136, no. 1, pp. 7-19.
Alinovi A, Barbieri L, Calvieri S, De Giacomo P, Guarrera M, Piraccini BM et al. Alopecia androgenetica maschile. Giornale Italiano di Dermatologia e Venereologia. 2001;136(1):7-19.
Alinovi, A. ; Barbieri, L. ; Calvieri, S. ; De Giacomo, P. ; Guarrera, M. ; Piraccini, B. M. ; Rebora, A. ; Rossi, A. ; Tosti, A. / Alopecia androgenetica maschile. In: Giornale Italiano di Dermatologia e Venereologia. 2001 ; Vol. 136, No. 1. pp. 7-19.
@article{1772d2781f334144bda11b1b44c1733b,
title = "Alopecia androgenetica maschile",
abstract = "Androgenetic alopecia is the most frequent cause of hair loss affecting at least 50{\%} of men by the age of 50. Male pattern hair loss affect the front-vertical scalp. Hairs in this area progressively become like vellus hairs. The development of androgenetic alopecia requires the interaction of genetic and hormonal factors. Although there is agreement that it is an inherited condition, it may not be genetically homogeneous. Several data have confirmed the significant role of androgens in the development of androgenetic alopecia. Dihydrotestosterone is currently thought to be the most potent androgen affecting the human hair growth cycle, with adverse effects in male pattern hair loss. The enzyme 5α-reductase is responsible for catalyzing the conversion of testosterone to dihydrotestosterone. It is now known that two separate isoenzymes of 5α-reductase exist: type I and type II, specifically localized within the hair follicle itself and in the innermost layer of the outer root sheath. The importance of type II 5α-reductase in the development of androgenetic alopecia is demonstrated by the evidence that individuals with hereditary type II 5α-reductase deficiency do not develop androgenetic alopecia. In men, the diagnosis of androgenetic alopecia can usually be confirmed by medical history and physical examination alone. Androgenetic alopecia can be treated with oral finasteride (inhibitor of type II 5α-reductase) or topical minoxidil. Oral finasteride at the dosage of 1 mg/day produced clinical improvement in up to 66{\%} of patients treated for 2 years. Moreover the exact role of the hair specialist is discussed and the dermatologist is confirmed as the more indicated specialist and for the field.",
keywords = "Alopecia, drug therapy, Alopecia, etiology, Finasteride therapeutic use, Minoxidil therapeutic use",
author = "A. Alinovi and L. Barbieri and S. Calvieri and {De Giacomo}, P. and M. Guarrera and Piraccini, {B. M.} and A. Rebora and A. Rossi and A. Tosti",
year = "2001",
language = "Italian",
volume = "136",
pages = "7--19",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Alopecia androgenetica maschile

AU - Alinovi, A.

AU - Barbieri, L.

AU - Calvieri, S.

AU - De Giacomo, P.

AU - Guarrera, M.

AU - Piraccini, B. M.

AU - Rebora, A.

AU - Rossi, A.

AU - Tosti, A.

PY - 2001

Y1 - 2001

N2 - Androgenetic alopecia is the most frequent cause of hair loss affecting at least 50% of men by the age of 50. Male pattern hair loss affect the front-vertical scalp. Hairs in this area progressively become like vellus hairs. The development of androgenetic alopecia requires the interaction of genetic and hormonal factors. Although there is agreement that it is an inherited condition, it may not be genetically homogeneous. Several data have confirmed the significant role of androgens in the development of androgenetic alopecia. Dihydrotestosterone is currently thought to be the most potent androgen affecting the human hair growth cycle, with adverse effects in male pattern hair loss. The enzyme 5α-reductase is responsible for catalyzing the conversion of testosterone to dihydrotestosterone. It is now known that two separate isoenzymes of 5α-reductase exist: type I and type II, specifically localized within the hair follicle itself and in the innermost layer of the outer root sheath. The importance of type II 5α-reductase in the development of androgenetic alopecia is demonstrated by the evidence that individuals with hereditary type II 5α-reductase deficiency do not develop androgenetic alopecia. In men, the diagnosis of androgenetic alopecia can usually be confirmed by medical history and physical examination alone. Androgenetic alopecia can be treated with oral finasteride (inhibitor of type II 5α-reductase) or topical minoxidil. Oral finasteride at the dosage of 1 mg/day produced clinical improvement in up to 66% of patients treated for 2 years. Moreover the exact role of the hair specialist is discussed and the dermatologist is confirmed as the more indicated specialist and for the field.

AB - Androgenetic alopecia is the most frequent cause of hair loss affecting at least 50% of men by the age of 50. Male pattern hair loss affect the front-vertical scalp. Hairs in this area progressively become like vellus hairs. The development of androgenetic alopecia requires the interaction of genetic and hormonal factors. Although there is agreement that it is an inherited condition, it may not be genetically homogeneous. Several data have confirmed the significant role of androgens in the development of androgenetic alopecia. Dihydrotestosterone is currently thought to be the most potent androgen affecting the human hair growth cycle, with adverse effects in male pattern hair loss. The enzyme 5α-reductase is responsible for catalyzing the conversion of testosterone to dihydrotestosterone. It is now known that two separate isoenzymes of 5α-reductase exist: type I and type II, specifically localized within the hair follicle itself and in the innermost layer of the outer root sheath. The importance of type II 5α-reductase in the development of androgenetic alopecia is demonstrated by the evidence that individuals with hereditary type II 5α-reductase deficiency do not develop androgenetic alopecia. In men, the diagnosis of androgenetic alopecia can usually be confirmed by medical history and physical examination alone. Androgenetic alopecia can be treated with oral finasteride (inhibitor of type II 5α-reductase) or topical minoxidil. Oral finasteride at the dosage of 1 mg/day produced clinical improvement in up to 66% of patients treated for 2 years. Moreover the exact role of the hair specialist is discussed and the dermatologist is confirmed as the more indicated specialist and for the field.

KW - Alopecia, drug therapy

KW - Alopecia, etiology

KW - Finasteride therapeutic use

KW - Minoxidil therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=0035032203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035032203&partnerID=8YFLogxK

M3 - Articolo

VL - 136

SP - 7

EP - 19

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 1

ER -